<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03957590</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317-311</org_study_id>
    <secondary_id>CTR20190198</secondary_id>
    <nct_id>NCT03957590</nct_id>
  </id_info>
  <brief_title>Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Patient With ESCC</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Localized Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to compare the efficacy
      and safety of BGB-A317 versus Placebo with chemoradiotherapy in Patients with Localized
      Esophageal Squamous Cell Carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of randomization up to 4 years, approximately</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate (ORR)</measure>
    <time_frame>From date of randomization up to 4 years, approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>From first determination of an objective response up to 4 years, approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>From date of randomization up to 4 years, approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in European Quality of Life-Core 30 Questionnaire index (EORTC QLQ-C30).</measure>
    <time_frame>From date of randomization to end of treatment ~2 years,</time_frame>
    <description>Scale consultant including to assess Global health status/Qol with range from minimum scores 1 as worse outcome and maximum scores 7 as higher values represent a better, Physical functioning, role functioning, Emotional functioning, Cognitive functioning, social functioning, fatigue, nausea and vomiting, pain dysponoea, insomnia, appetite loss, constipation, diarrhea and finical difficulties with range from maximum scores 4 as worse outcome and from minimum scores 1 as higher values represent as better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire esophageal cancer module (EORTC QLQ-OES18).</measure>
    <time_frame>From date of randomization to end of treatment, ~2years</time_frame>
    <description>Total 18 questions to assess your symptoms or problems during the past week with the range from minimum scores 1 as better outcome and maximum 4 as worst outcomes. includes whether any difficult to eat solids, liquids food or not， whether it is difficult to swallow ， whether the sense of smell and conversation are normal or not， whether have Symptoms include cough, indigestion or heartburn, acid reflux and pain or not .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of treatment-emergent adverse events (TEAEs) graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events'.</measure>
    <time_frame>From date of enrollment up to 4 years, approximately.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma (ESCC)</condition>
  <arm_group>
    <arm_group_label>Arm A: Tislelizumab （BGB-A317）combined with chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tislelizumab(BGB-A317) will be administrated at dose of 200 mg intravenous dosing (IV) once every cycle (Q3W), Paclitaxel 135 mg/m² will be administered as an intravenous infusion on Day 1 of every cycle (3 weeks)， total 2 Cycle; Cisplatin 25 mg/m² will be administered as an intravenous infusion on Day 1 to 3 of every cycle (3 weeks) Total 2 Cycle. Radiotherapy total dose of 50.4 Gy in 28 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo combined with chemoradiotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administrated at does of 200 mg intravenous dosing (IV)once every cycle (Q3W); Paclitaxel 135 mg/m² will be administered as an intravenous infusion on Day 1 of every cycle (3 weeks) ， total 2 Cycle; Cisplatin 25 mg/m² will be administered as an intravenous infusion on Day 1 to 3 of every cycle (3 weeks), total 2 Cycle. Radiotherapy total dose of 50.4 Gy in 28 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab(BGB-A317 combined with chemoradiotherapy.</intervention_name>
    <description>Tislelizumab with concurrent chemoradiotherapy</description>
    <arm_group_label>Arm A: Tislelizumab （BGB-A317）combined with chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo combined with chemoradiotherapy</intervention_name>
    <description>Placebo with concurrent chemoradiotherapy</description>
    <arm_group_label>Arm B: Placebo combined with chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 75 years on the day of signing the informed consent form

          -  Histologically confirmed diagnosis of localized ESCC

          -  Measurable and/or non-measurable disease defined per RECIST v1.1

          -  ECOG Performance Status ≤ 1

          -  Adequate organ function

        Exclusion Criteria:

          -  Indicators of severe malnutrition

          -  Clinically uncontrolled pleural effusion, pericardial effusion, or ascites requiring
             frequent drainage or medical intervention within 2 weeks prior to randomization

          -  Known to be intolerable or resistant to treatment with the protocol-specified
             chemotherapy

          -  Received prior radiotherapy or therapies targeting PD-1, PD-L1, PD-L2 or other
             immune-oncology therapies

          -  Active autoimmune diseases or history of autoimmune diseases that may relapse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weihu Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zefen Xiao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>+1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northern Jiangsu people's hospital</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

